232 related articles for article (PubMed ID: 11362628)
1. FDA reform: activists' proposals. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):6-8. PubMed ID: 11362628
[TBL] [Abstract][Full Text] [Related]
2. Policy statement on FDA reform. Food and Drug Administration.
Baker R; Delaney M; Getty J; Grinberg L; Levin J
BETA; 1995 Sep; ():45-6. PubMed ID: 11362893
[TBL] [Abstract][Full Text] [Related]
3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
4. The growing debate over FDA reform. Food and Drug Administration.
Link D
GMHC Treat Issues; 1996 Jan; 10(1):1-5. PubMed ID: 11363372
[TBL] [Abstract][Full Text] [Related]
5. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
6. Reform at FDA: faster access to promising drugs? Food and Drug Administration.
Baker R
BETA; 1995 Jun; ():39-40. PubMed ID: 11362545
[TBL] [Abstract][Full Text] [Related]
7. The role of the FDA in the effort against AIDS.
Young FE
Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
[TBL] [Abstract][Full Text] [Related]
8. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
9. Whatever happened to expanded access?
Notes Undergr; 1997; (No 35):2-3. PubMed ID: 11364564
[TBL] [Abstract][Full Text] [Related]
10. Europeans outraged over expanded access.
Alcorn K; Nary G; Pernet AG; Surchio JL; Weiner JD
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):48-51. PubMed ID: 11363519
[TBL] [Abstract][Full Text] [Related]
11. FDA reform floated in DC. Food and Drug Administration.
Hodel D
GMHC Treat Issues; 1995 Jun; 9(6):6-7. PubMed ID: 11362691
[TBL] [Abstract][Full Text] [Related]
12. FDA reform signed into law. Food and Drug Administration.
James JS
AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
[TBL] [Abstract][Full Text] [Related]
13. The FDA and "privatization"--the drug approval process.
Rutherford EM
Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
[No Abstract] [Full Text] [Related]
14. The National Task Force on AIDS Drug Development: a progress report.
Levin J
BETA; 1995 Jun; ():62-3. PubMed ID: 11362547
[TBL] [Abstract][Full Text] [Related]
15. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
[TBL] [Abstract][Full Text] [Related]
16. Federal AIDS policy issues today.
James JS
AIDS Treat News; 1997 Aug; (No 276):2-8. PubMed ID: 11364520
[TBL] [Abstract][Full Text] [Related]
17. FDA reform in Congress: interview with Peter Barton Hutt. Food and Drug Administration. Interview by John S. James.
Hutt PB
AIDS Treat News; 1996 Apr; (no 245):4-5. PubMed ID: 11363623
[TBL] [Abstract][Full Text] [Related]
18. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell MC
Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
[No Abstract] [Full Text] [Related]
19. 3TC and protease inhibitors: citizen's petition asks faster approval.
AIDS Treat News; 1995 Apr; (no 220):5. PubMed ID: 11362321
[TBL] [Abstract][Full Text] [Related]
20. Activists now urge caution on approval of new AIDS drug.
MacIlwain C
Nature; 1993 Sep; 365(6445):378. PubMed ID: 8413575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
